Last Updated: November 19, 2026

REVUFORJ Drug Patent Profile

« Back to Dashboard


Which patents cover Revuforj, and when can generic versions of Revuforj launch?

Revuforj is a drug marketed by Syndax and is included in one NDA. There are three patents protecting this drug.

The generic ingredient in REVUFORJ is revumenib citrate. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the revumenib citrate profile page.

DrugPatentWatch® Generic Entry Outlook for Revuforj

Revuforj will be eligible for patent challenges on November 15, 2028. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be June 8, 2037. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Start Trial

AI Deep Research
Questions you can ask:
  • What is the 5 year forecast for REVUFORJ?
  • What are the global sales for REVUFORJ?
  • What is Average Wholesale Price for REVUFORJ?
Summary for REVUFORJ
US Patents:3
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
What excipients (inactive ingredients) are in REVUFORJ?REVUFORJ excipients list
DailyMed Link:REVUFORJ at DailyMed
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for REVUFORJ
Generic Entry Date for REVUFORJ*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:

TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for REVUFORJ
Drug ClassMenin Inhibitor
Mechanism of ActionMenin Inhibitors

US Patents and Regulatory Information for REVUFORJ

REVUFORJ is protected by five US patents and four FDA Regulatory Exclusivities.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of REVUFORJ is ⤷  Start Trial.

This potential generic entry date is based on patent ⤷  Start Trial.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Syndax REVUFORJ revumenib citrate TABLET;ORAL 218944-001 Nov 15, 2024 RX Yes No ⤷  Start Trial ⤷  Start Trial Y ⤷  Start Trial
Syndax REVUFORJ revumenib citrate TABLET;ORAL 218944-003 Nov 15, 2024 RX Yes Yes ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Syndax REVUFORJ revumenib citrate TABLET;ORAL 218944-001 Nov 15, 2024 RX Yes No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Syndax REVUFORJ revumenib citrate TABLET;ORAL 218944-002 Nov 15, 2024 RX Yes No ⤷  Start Trial ⤷  Start Trial Y ⤷  Start Trial
Syndax REVUFORJ revumenib citrate TABLET;ORAL 218944-003 Nov 15, 2024 RX Yes Yes ⤷  Start Trial ⤷  Start Trial Y ⤷  Start Trial
Syndax REVUFORJ revumenib citrate TABLET;ORAL 218944-002 Nov 15, 2024 RX Yes No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Syndax REVUFORJ revumenib citrate TABLET;ORAL 218944-002 Nov 15, 2024 RX Yes No ⤷  Start Trial ⤷  Start Trial Y Y ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for REVUFORJ

When does loss-of-exclusivity occur for REVUFORJ?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Patent: 17278950
Estimated Expiration: ⤷  Start Trial

Patent: 21258089
Estimated Expiration: ⤷  Start Trial

Patent: 24202700
Estimated Expiration: ⤷  Start Trial

Brazil

Patent: 2018075260
Estimated Expiration: ⤷  Start Trial

Patent: 2024002146
Estimated Expiration: ⤷  Start Trial

Canada

Patent: 24180
Estimated Expiration: ⤷  Start Trial

Patent: 97462
Estimated Expiration: ⤷  Start Trial

China

Patent: 9743875
Estimated Expiration: ⤷  Start Trial

Croatia

Patent: 0201771
Estimated Expiration: ⤷  Start Trial

Cyprus

Patent: 24834
Estimated Expiration: ⤷  Start Trial

Denmark

Patent: 68966
Estimated Expiration: ⤷  Start Trial

European Patent Office

Patent: 68966
Estimated Expiration: ⤷  Start Trial

Patent: 05215
Estimated Expiration: ⤷  Start Trial

Hungary

Patent: 51451
Estimated Expiration: ⤷  Start Trial

Israel

Patent: 3586
Estimated Expiration: ⤷  Start Trial

Patent: 3267
Estimated Expiration: ⤷  Start Trial

Patent: 8381
Estimated Expiration: ⤷  Start Trial

Patent: 1844
Estimated Expiration: ⤷  Start Trial

Japan

Patent: 07302
Estimated Expiration: ⤷  Start Trial

Patent: 61390
Estimated Expiration: ⤷  Start Trial

Patent: 19517548
Estimated Expiration: ⤷  Start Trial

Patent: 22058514
Estimated Expiration: ⤷  Start Trial

Patent: 24045176
Estimated Expiration: ⤷  Start Trial

Patent: 25113339
Estimated Expiration: ⤷  Start Trial

Lithuania

Patent: 68966
Estimated Expiration: ⤷  Start Trial

Mexico

Patent: 1228
Patent: INHIBIDORES DE LA INTERACCIÓN DE MENINA-LEUCEMIA DE LINAJE MIXTO. (INHIBITORS OF THE MENIN-MLL INTERACTION)
Estimated Expiration: ⤷  Start Trial

Patent: 18015252
Patent: INHIBIDORES DE LA INTERACCION DE MENINA-LEUCEMIA DE LINAJE MIXTO. (INHIBITORS OF THE MENIN-MLL INTERACTION.)
Estimated Expiration: ⤷  Start Trial

Patent: 21003939
Patent: INHIBIDORES DE LA INTERACCION DE MENINA-LEUCEMIA DE LINAJE MIXTO. (INHIBITORS OF THE MENIN-MLL INTERACTION.)
Estimated Expiration: ⤷  Start Trial

Patent: 23002982
Patent: INHIBIDORES DE LA INTERACCION DE MENINA-LEUCEMIA DE LINAJE MIXTO. (INHIBITORS OF THE MENIN-MLL INTERACTION.)
Estimated Expiration: ⤷  Start Trial

New Zealand

Patent: 8203
Patent: Inhibitors of the menin-mll interaction
Estimated Expiration: ⤷  Start Trial

Poland

Patent: 68966
Estimated Expiration: ⤷  Start Trial

Portugal

Patent: 68966
Estimated Expiration: ⤷  Start Trial

Russian Federation

Patent: 19100040
Patent: ИНГИБИТОРЫ ВЗАИМОДЕЙСТВИЯ МЕНИН-MLL
Estimated Expiration: ⤷  Start Trial

Slovenia

Patent: 68966
Estimated Expiration: ⤷  Start Trial

South Africa

Patent: 1900150
Patent: INHIBITORS OF THE MENIN-MLL INTERACTION
Estimated Expiration: ⤷  Start Trial

South Korea

Patent: 2436430
Estimated Expiration: ⤷  Start Trial

Patent: 2916887
Estimated Expiration: ⤷  Start Trial

Patent: 190017012
Estimated Expiration: ⤷  Start Trial

Patent: 220123727
Estimated Expiration: ⤷  Start Trial

Patent: 250079083
Estimated Expiration: ⤷  Start Trial

Spain

Patent: 31084
Estimated Expiration: ⤷  Start Trial

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering REVUFORJ around the world.

Country Patent Number Title Estimated Expiration
Australia 2017278950 ⤷  Start Trial
Australia 2021258089 ⤷  Start Trial
Australia 2024202700 ⤷  Start Trial
Brazil 112018075260 ⤷  Start Trial
Brazil 122024002146 ⤷  Start Trial
Canada 3024180 ⤷  Start Trial
Canada 3297462 ⤷  Start Trial
>Country >Patent Number >Title >Estimated Expiration

REVUFORJ (Revumenib) Market Dynamics, Patent Position, and Financial Trajectory

Last updated: October 13, 2026

Revuforj is Syndax Pharmaceuticals' oral menin inhibitor for relapsed or refractory acute leukemia with a KMT2A translocation. The FDA granted accelerated approval on Nov. 15, 2024, making Revuforj the first approved menin-pathway therapy in this setting.[1] Its commercial opportunity is concentrated but strategically important: the eligible population is small, treatment is specialist-driven, and the product addresses a high-mortality molecular subgroup with limited approved alternatives.

The financial trajectory depends on three variables: rapid identification of KMT2A-positive patients, conversion of clinical-trial use into routine treatment, and expansion into frontline or broader acute myeloid leukemia populations. In 2024, Revuforj had no meaningful commercial revenue base because approval occurred late in the year. The primary commercial buildout is therefore a 2025-and-beyond event.

What is Revuforj and what FDA indication does it have?

Revuforj is revumenib, an oral small-molecule inhibitor of the menin-KMT2A interaction. The FDA-approved indication covers adults and pediatric patients age 1 year and older with relapsed or refractory acute leukemia and a lysine methyltransferase 2A gene translocation, commonly called KMT2A-rearranged leukemia.[1]

Attribute Revuforj
Active ingredient Revumenib
Developer Syndax Pharmaceuticals
Drug class Menin inhibitor
FDA approval Nov. 15, 2024
Approval pathway Accelerated approval
Disease setting Relapsed or refractory acute leukemia
Biomarker KMT2A translocation
Dosage form Oral tablets and oral capsules
Patient population Adults and pediatric patients age 1 year and older
Regulatory basis Response rate and duration of response in a single-arm study
Key confirmatory obligation Randomized confirmatory development in earlier-line disease

The approval was based principally on the AUGMENT-101 study, which enrolled patients with relapsed or refractory acute leukemia carrying a KMT2A rearrangement. The FDA label identifies differentiation syndrome, QTc prolongation, and embryofetal toxicity among the principal safety risks.[1]

How large is the Revuforj commercial market?

The initial market is an orphan oncology market rather than a broad acute myeloid leukemia market. KMT2A rearrangements occur in a minority of acute leukemias, with a higher incidence in infant and pediatric acute lymphoblastic leukemia and a clinically important presence in adult acute myeloid leukemia.

Commercial demand is supported by four factors:

  1. KMT2A-rearranged disease has poor outcomes after relapse.
  2. The biomarker is identifiable through cytogenetic and molecular testing.
  3. There was no previously approved targeted menin inhibitor in the United States.
  4. Treatment is used in a setting where physicians have limited durable options.

The market is constrained by the narrow label, low prevalence, competing salvage regimens, transplantation pathways, and the need to confirm the diagnosis before prescribing.

Patient flow and treatment economics

The commercial funnel is likely to run through academic leukemia centers, transplant hospitals, pediatric oncology networks, and specialty pharmacies. The highest-value patients are those who:

  • Have confirmed KMT2A rearrangement;
  • Have relapsed or refractory disease;
  • Are medically fit for oral therapy;
  • Have a treatment objective that includes remission or bridge to transplantation.

Revuforj can generate revenue through repeated treatment cycles, but treatment duration will vary by response, toxicity, transplantation, and disease progression. The product's economic value is higher when it produces a remission that enables allogeneic stem-cell transplantation.

What is the Revuforj pricing and reimbursement outlook?

Syndax launched Revuforj as a specialty oncology product with pricing intended for a rare, high-acuity population. The relevant commercial metrics are gross-to-net-adjusted sales, treatment duration, payer approval rates, and the percentage of patients treated through commercial insurance, Medicare, Medicaid, or manufacturer assistance programs.

Reimbursement risk is moderate rather than negligible. Payers generally recognize FDA-approved oncology drugs, but the accelerated-approval status, high treatment cost, pediatric use, and biomarker-confirmation requirement can create prior-authorization friction.

The key market-access requirements include:

  • Documentation of KMT2A rearrangement;
  • Confirmation of relapsed or refractory disease;
  • Appropriate dosing by age and concomitant medications;
  • Monitoring for differentiation syndrome and QTc effects;
  • Coordination with a specialty pharmacy or oncology distributor.

What is the financial trajectory for Revuforj and Syndax?

Revuforj's financial profile has three phases.

Phase one: launch investment

The first phase includes sales-force deployment, medical-affairs hiring, payer contracting, diagnostic education, patient-support programs, inventory creation, and post-approval studies. These costs can depress operating margins before revenue reaches scale.

Syndax's commercial strategy is likely to prioritize high-volume leukemia centers rather than broad community-oncology coverage. That approach limits selling expense relative to a mass-market oncology launch but requires intensive physician education and molecular-testing support.

Phase two: orphan-market penetration

The second phase depends on the speed at which physicians adopt Revuforj after failure of existing salvage therapy. Early revenue is likely to be concentrated among:

  • Academic medical centers;
  • Patients previously enrolled in AUGMENT-101;
  • Adults with relapsed acute myeloid leukemia;
  • Pediatric and young-adult leukemia programs;
  • Patients being evaluated for transplantation.

Revenue growth can be rapid from a small base if diagnosis and access barriers are managed. The main limitation is the number of newly diagnosed eligible patients, not general awareness of the drug.

Phase three: label expansion

The largest financial upside requires use in earlier-line disease or combinations. Syndax's development strategy has focused on moving menin inhibition into broader treatment settings, including combinations with established acute leukemia regimens.[2] A successful frontline or consolidation indication would expand the addressable population and increase treatment duration.

The commercial value of Revuforj is therefore asymmetric:

Scenario Commercial effect
Narrow relapsed/refractory label only Specialist orphan product with controlled but limited revenue
Durable responses with bridge to transplant Higher treatment persistence and stronger physician adoption
Positive confirmatory study Reduced regulatory risk and broader payer confidence
Frontline approval Material expansion of eligible patients
Combination-label expansion Greater use across treatment lines and higher annual revenue per patient
Confirmatory failure Risk to approval status, adoption, and valuation

Syndax's revenue trajectory should be assessed against product sales, cash burn, research-and-development spending, and the need for additional financing. Early product revenue does not automatically translate into profitability because post-approval studies and commercial infrastructure remain costly.

What patents protect Revuforj?

Revuforj's exclusivity position is based on a combination of patent rights, regulatory exclusivity, orphan-drug protections, and pending patent applications. The relevant patent categories include:

  • Revumenib composition-of-matter patents;
  • Crystal form and salt patents;
  • Pharmaceutical composition patents;
  • Oral dosage-form patents;
  • Methods of treating KMT2A-rearranged leukemia;
  • Combination-treatment patents;
  • Manufacturing and process patents.

The commercial importance of each category differs. Composition-of-matter rights generally provide the strongest protection. Method-of-use patents can protect particular biomarker-defined populations but may be more vulnerable to non-infringement arguments if a generic omits or disputes the patented indication. Formulation and process patents can complicate generic development but rarely replace a strong composition patent.

A definitive patent-expiration analysis requires the current FDA Orange Book listing, USPTO patent-term data, terminal disclaimers, patent-term adjustments, and any applicable pediatric extensions. The public FDA approval materials establish the regulatory protection framework but do not by themselves establish the complete enforceable patent term.[1]

When does Revuforj lose regulatory exclusivity?

Revuforj received orphan-drug designation for the approved disease setting. Orphan-drug exclusivity generally prevents FDA approval of the same drug for the same indication for seven years from approval, subject to statutory exceptions.[3]

The approval also carries accelerated-approval obligations. The duration of market protection will depend on:

  • The seven-year orphan exclusivity period;
  • Listed patents and their effective expiration dates;
  • Any six-month pediatric exclusivity;
  • Patent-term adjustment or extension;
  • The outcome of confirmatory trials;
  • Potential withdrawal if required clinical benefit is not verified.

Because Revuforj was approved in November 2024, the orphan-exclusivity period would ordinarily extend into November 2031, subject to the legal details of the designation and indication.

What is the Orange Book status of Revuforj?

Revuforj is an FDA-approved small molecule, so its approved product and applicable patents are evaluated through the Hatch-Waxman framework. The Orange Book is the controlling source for listed patents, patent-use codes, and exclusivity information.[4]

Potential future generic challenges could target:

  • The active ingredient;
  • The listed composition-of-matter patent;
  • The dosage form;
  • Patent-term calculations;
  • Method-of-use claims;
  • The scope of the approved indication.

A Paragraph IV certification would create litigation risk if a generic applicant asserts that a listed patent is invalid, unenforceable, or not infringed. The timing of any generic launch would depend on the ANDA filing date, the certification, patent litigation, a 30-month stay, pediatric exclusivity, and the outcome of any settlement.

Which companies are challenging Revuforj?

No approved generic competitor or biosimilar can directly compete with Revuforj at the time of its initial launch. Revumenib is a small molecule, so biosimilar regulation is not applicable.

The most relevant competitive threat is another menin inhibitor, particularly ziftomenib from Kura Oncology. Ziftomenib targets the same general biological pathway and is being developed in KMT2A-rearranged and NPM1-mutated acute myeloid leukemia.[5] Other competition includes:

  • Venetoclax-based salvage regimens;
  • FLT3 inhibitors for FLT3-mutated disease;
  • IDH inhibitors for IDH1- or IDH2-mutated disease;
  • Intensive chemotherapy;
  • Clinical trials;
  • Allogeneic stem-cell transplantation.

Revuforj has a first-mover advantage, but the menin-inhibitor market can become more competitive if a rival obtains an approval in a larger molecular segment such as NPM1-mutated acute myeloid leukemia.

How strong is the Revuforj patent and market position?

Revuforj's market position is strongest in the following areas:

  • First approved menin inhibitor;
  • Orphan-drug protection;
  • High unmet need in KMT2A-rearranged leukemia;
  • Specialist prescribing concentration;
  • Biomarker-defined patient selection;
  • Potential to become a platform for combination therapy.

Its principal weaknesses are:

  • Small initial patient population;
  • Accelerated-approval obligations;
  • Safety monitoring requirements;
  • Dependence on molecular testing;
  • Potential competition from other menin inhibitors;
  • Limited commercial history;
  • Exposure to clinical-trial failure in earlier-line disease.

The patent estate is strategically valuable if composition-of-matter protection extends into the late 2030s or beyond. Exact enforceable dates should be determined from the current patent and Orange Book records rather than from approval-date estimates.

What litigation and settlement risks affect Revuforj?

The main near-term legal risk is not a current generic challenge but future Hatch-Waxman litigation. Possible disputes include patent validity, written description, enablement, obviousness, infringement, and the scope of method-of-use claims.

Potential settlement structures could include:

  • A licensed generic entry date;
  • Authorized-generic supply;
  • A covenant not to sue for specific indications;
  • Restrictions tied to patent expiration;
  • Pediatric exclusivity treatment;
  • Different entry dates for different dosage forms.

No broad biosimilar litigation framework applies because Revuforj is not a biologic.

How does Revuforj compare with ziftomenib?

Factor Revuforj Ziftomenib
Developer Syndax Pharmaceuticals Kura Oncology
Mechanism Menin inhibition Menin inhibition
Lead biomarker KMT2A translocation KMT2A-rearranged and NPM1-mutated AML development
Regulatory position First FDA-approved menin inhibitor Development-stage competitor at Revuforj approval
Initial commercial advantage Yes No at Revuforj launch
Competitive risk Narrow label and confirmatory obligations Clinical and regulatory execution risk
Market expansion Earlier-line disease and combinations Potentially broader molecular coverage

The strategic question is whether Revuforj remains a narrowly targeted rescue therapy or becomes the anchor product for menin-based treatment across multiple acute leukemia subtypes.

Key Takeaways

  • Revuforj is revumenib, Syndax's first commercial product and the first FDA-approved menin inhibitor.
  • FDA approval occurred on Nov. 15, 2024, for relapsed or refractory acute leukemia with a KMT2A translocation.
  • The initial market is small, specialized, and biomarker-dependent but has high unmet need.
  • Revenue growth depends on uptake at leukemia centers, reimbursement execution, treatment duration, and transplant-bridging use.
  • The largest financial upside requires confirmatory success and expansion into frontline or combination therapy.
  • Orphan-drug exclusivity would ordinarily provide protection into November 2031, subject to statutory and designation-specific details.
  • Generic litigation is a future Hatch-Waxman risk; biosimilar competition is not relevant.
  • Ziftomenib is the most important mechanistic competitor because it targets the same menin pathway and may pursue broader acute myeloid leukemia populations.

FAQs About Revuforj Exclusivity, Sales, and Competition

Is Revuforj a biologic or a small-molecule drug?

Revuforj is an oral small-molecule drug. Biosimilar rules do not apply; future generic competition would proceed through the ANDA pathway.

What biomarker is required before prescribing Revuforj?

The patient must have acute leukemia with a KMT2A translocation. Molecular or cytogenetic testing is required to establish eligibility.

Can Revuforj be used before relapse?

The original FDA approval is for relapsed or refractory disease. Earlier-line use would generally require a later approval, a clinical trial, or another legally authorized treatment pathway.

Does Revuforj have orphan-drug exclusivity?

Yes. Revuforj received orphan-drug protection for its rare leukemia indication. The statutory period is generally seven years from approval, subject to applicable exceptions and regulatory conditions.

What is the largest threat to Revuforj revenue?

The largest threats are failure to expand beyond the narrow initial indication, slow molecular testing and reimbursement, confirmatory-trial failure, and competition from another menin inhibitor with broader acute myeloid leukemia coverage.

References

  1. U.S. Food and Drug Administration. (2024). Revuforj (revumenib) prescribing information and approval announcement. https://www.fda.gov
  2. Syndax Pharmaceuticals, Inc. (2025). Annual report on Form 10-K. U.S. Securities and Exchange Commission. https://www.sec.gov
  3. U.S. Food and Drug Administration. (2023). Orphan drug designation and exclusivity. https://www.fda.gov
  4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov
  5. Kura Oncology, Inc. (2024). Clinical development information for ziftomenib. https://www.kuraoncology.com

More… ↓

⤷  Start Trial

DrugChatter Q&A for REVUFORJ

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.